Page 103 - 88_01
P. 103
ANALES Spain. Int J Pharmacol. 2016;12(6):612–6.
RANF 92. Schmidt M, Pedersen L, Maeng M, Lassen JF, Lash TL, Nielsen TT, et
www.analesranf.com al.. Nonsteroidal antiinflammatory drug use and cardiovascular risks
after coronary stent implantation. Pharmacotherapy.
of non-steroidal anti- inflammatory drugs and risk of incident myo- 2011;31(5):458–68.
cardial infarction and heart failure, and all-cause mortality in the 93. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT.
Australian veteran community. Br J Clin Pharmacol. Non-steroidal anti- inflammatory drug use and risk of atrial fibri-
2010;69(6):689–700. llation or flutter: population based case-control study. BMJ.
81. Mangoni AA, Woodman RJ, Gilbert AL, Knights KM. Use of non-ste- 2011;343:d3450.
roidal anti-inflammatory drugs and risk of ischemic and hemorrhagic 94. Schmidt M, Christiansen CF, Horváth-Puhó E, Glynn RJ, Rothman
stroke in the Australian veteran community. Pharmacoepidemiol KJ, Sørensen HT. Non- steroidal anti-inflammatory drug use and
Drug Saf. 2010;19:490–8. risk of venous thromboembolism. J Thromb Haemost.
82. McGettigan P, Han P, Jones L, Whitaker D, Henry D. Selective COX- 2011;9(7):1326–33.
2 inhibitors, NSAIDs and congestive heart failure: Differences bet- 95. Schmidt M, Hováth-Puhó E, Christiansen CF, Petersen KL, Bøtker
ween new and recurrent cases. Br J Clin Pharmacol. HE, Sørensen HT. Preadmission use of nonaspirin nonsteroidal
2008;65(6):927–34. anti-inflammatory drugs and 30-day stroke mortality. Neurology.
83. Olsen AMS, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, 2014;83(22):2013–22.
et al.. Long-term cardiovascular risk of nonsteroidal anti-inflamma- 96. Shin J-Y, Park M-J, Lee SH, Choi S-H, Kim M-H, Choi N-K, et al. Risk
tory drug use according to time passed after first-time myocardial of intracranial haemorrhage in antidepressant users with concurrent
infarction: A nationwide cohort study. Circulation. use of non-steroidal anti-inflammatory drugs: nationwide propensity
2012;126(16):1955–63. score matched study. BMJ. 2015;351:h3517.
84. Schjerning Olsen A-M, Gislason GH, McGettigan P, Fosbøl E, Søren- 97. Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss
sen R, Hansen ML, et al. Association of NSAID Use With Risk of Ble- S. Cardiovascular outcomes in new users of coxibs and nonste-
eding and Cardiovascular Events in Patients Receiving Antithrombotic roidal antiinflammatory drugs: High-risk subgroups and time
Therapy After Myocardial Infarction. JAMA. 2015;313(8):805. course of risk. Arthritis Rheum. 2006;54(5):1378–89.
85. Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with 98. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S,
aspirin alone and the risk of myocardial infarction. Arch Intern Med. Mogun H, et al.. Subgroup analyses to determine cardiovascular
2004;164(8):852–6. risk associated with nonsteroidal antiinflammatory drugs and coxibs
86. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. in specific patient groups. Arthritis Care Res. 2008;59(8):1097–
COX-2 selective non- steroidal anti-inflammatory drugs and risk 104.
of serious coronary heart disease. Lancet. 2002;360(9326):1071– 99. Spalding WM, Reeves MJ, Whelton A. Thromboembolic cardiovas-
3. cular risk among arthritis patients using cyclooxygenase-2-selective
87. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-
KT, Stein CM, et al. Cardiovascular Risks of Nonsteroidal Antiin- inflammatory drugs. Am J Ther. 2007;14(1):3–12.
flammatory Drugs in Patients After Hospitalization for Serious Co- 100. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the
ronary Heart Disease. Circ Cardiovasc Qual Outcomes. risk of acute myocardial infarction. Arthritis Rheum.
2009;2(3):155–63. 2006;55(4):531–6. Diseases: A nationwide case-control study.
88. Roumie CL, Mitchel EF, Kaltenbach L, Arbogast PG, Gideon P, Griffin PLoS One. 2015;10(5):1–13.
MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk 102. Van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings
for stroke. Stroke. 2008;39(7):2037–45. RMC. The balance between severe cardiovascular and gastrointesti-
89. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin nal events among users of selective and non- selective non-steroidal
MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668–73.
cardiovascular events–stroke, acute myocardial infarction, and death 103. Van Staa TP, Rietbrock S, Setakis E, Leufkens HGM. Does the varied
from coronary heart disease. Pharmacoepidemiol Drug Saf. use of NSAIDs explain the differences in the risk of myocardial in-
2009;18:1053–63. farction? J Intern Med. 2008;264(5):481–92.
90. Serrano JLS, Burillo JMT, Arias ÁA, Carreras MIM, Gámez JCV. 104. Wade KC, Ellenberg JH, Ph D, Grosser T, Colleen M, Kimmel SE, et
Cardiovascular Risk Associated with the Use of non Steroidal Anti- al.. Exogenous estrogen does not attenuate the association between
inflammatory Drugs . Rev Esp Salud Publica. 2015;89(6):607-13.
91. Serrano JLS, Burillo JMT, Arias ÁA, Ferrer EZ, Lluch MTG, Gámez JCV.
Cardiovascular risk associated with the use of non steroidal anti-in-
flammatory drugs, cases and controls study in a health care area in
Análisis y evaluación del riesgo cardiovascular y gastrointestinal de los antiinfla- 101
matorios no esteroideos inhibidores selectivos y no selectivos de ciclooxigenasa
Antonio Margo
An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103
